Step-Therapy Denial and Appeal Documentation
A prescriber sends a new prescription for adalimumab 40 mg/0.8 mL subcutaneous every other week for a patient with moderate-to-severe Crohn's disease. The patient's commercial plan requires step therapy with a conventional immunosuppressant before adalimumab. The pharmacy submits the prior authorization; the plan denies: 'Step therapy not met-no claim history for azathioprine or 6-mercaptopurine.' The prescriber's chart notes document a 10-week trial of azathioprine that was discontinued due to pancreatitis, but the pharmacy's records do not show the azathioprine because the patient filled it at another pharmacy. The patient is symptomatic and asks if they can just pay cash for the adalimumab. The cash price is $6,800 per month. The denial letter gives 60 days to appeal.
1. What type of denial is this, and what is the first step to resolve it?
Read the worked answer
This is a step-therapy denial, not a final medical-necessity denial. The plan needs evidence that the patient tried and failed or could not tolerate a required conventional therapy. The first step is to obtain the prescriber's chart notes documenting the azathioprine trial: dates, dose, duration, reason for discontinuation (pancreatitis), and relevant labs. The pharmacy should send these records with a letter of medical necessity or appeal, depending on the plan's process. The technician should not dispense adalimumab and assume payment. The 60-day appeal window gives time, but the patient is symptomatic, so the prescriber should be contacted promptly.
2. How should the pharmacy and prescriber document the prior azathioprine trial to meet the step-therapy requirement?
Read the worked answer
The documentation should show that the step-therapy drug was actually tried at an adequate dose and duration. The prescriber's notes should include the start and stop dates, the dose of azathioprine, the diagnosis, the adverse effect of pancreatitis, and the clinical decision to discontinue. Lab evidence such as lipase or amylase and any hospitalization should be included if available. A prescriber attestation can explain that the patient could not tolerate the drug. The pharmacy can request the other pharmacy's fill history with the patient's authorization, but the prescriber's records are stronger. Submit a complete packet, not just a claim that the patient 'failed' therapy.
3. The patient wants to pay cash. What should the technician explain about cash purchase, insurance, and future coverage?
Read the worked answer
The patient may pay cash, but the technician should explain the consequences. A cash purchase will not be submitted to the plan, so it will not count toward the deductible or out-of-pocket maximum, and the plan may still require step therapy for future fills. The patient should receive an itemized receipt in case they later seek reimbursement, but the plan is not obligated to reimburse a cash purchase for a drug that required PA. At $6,800 per month, the patient should first ask about manufacturer patient assistance or a foundation program. The pharmacy should also continue the appeal so the patient has coverage if the drug is approved. Do not submit the cash claim to insurance later without checking.